Clinical Trial News

Neurocrine Biosciences reports positive Phase II results for NBI-1117568, an oral schizophrenia treatment, showing significant symptom reduction and good tolerability.

Gain Therapeutics announces positive Phase 1 results for GT-02287, showing safety, tolerability, and target engagement, on track for Phase 1b trial in Q4 2024.

A study by the Doherty Institute found delaying COVID-19 booster doses offers no immunological benefits, supporting immediate booster administration for maintaining high immunity levels. The study, published in The Journal of Clinical Investigation, showed no difference in immune responses between immediate and delayed booster recipients, highlighting the need for longer-lasting vaccine protection.

Ubrelvy (ubrogepant) showed 73% more effectiveness in reducing migraine disability within 2 hours compared to placebo in a clinical trial, potentially improving quality of life for migraine sufferers.

Repare Therapeutics Inc. is focusing on advancing its clinical-stage oncology programs, including lunresertib, camonsertib, RP-1664, and RP-3467, with upcoming clinical milestones and potential near-term registration-enabling studies. The company plans to reduce its workforce by 25% and expects to extend its cash runway into the second half of 2026.

Families of children with food allergies face constant vigilance and emotional burden due to the lack of a cure. FDA-approved treatments like oral immunotherapy for peanut allergy and injectable medication for multiple food allergies reduce worry about accidental ingestion but do not allow carefree eating. Ongoing clinical trials at Lurie Children's Hospital explore innovative therapies, including a peanut patch and a dissolvable tablet under the tongue, aiming to minimize severe reactions and offer families peace of mind.

Transcenta Holding Limited announced interim results for the six months ended June 30, 2024, highlighting clinical progress with osemitamab (TST001) in G/GEJ cancer, safety and PK data consistency in U.S. and Chinese patients, collaboration with Agilent for Claudin18.2 CDx Assay, and positive results from blosozumab (TST002) SAD study for osteoporosis. The company also completed enrollment for the FIH trial of anti-GREMLIN-1 antibody TST003 and made advancements in bioprocessing technology.

Cell and gene therapy sectors are rapidly advancing, with approvals, clinical trials, and new therapies emerging. Notable developments include Legend Biotech's Carvykti approval in China, JW Therapeutics' relma-cel approval for MCL, Galapagos' GLPG5101 IND clearance, CARsgen's satri-cel trial enrollment completion, Tome Biosciences' layoffs, Tern Therapeutics' launch with $15 million, Navigator Medicines' $100 million series A, and Borealis Biosciences' $150 million Series A funding.

This study analyzed 1632 HPV clinical trials registered worldwide between 1999 and 2023, finding most were retrospectively registered in ClinicalTrials.gov, conducted in North America, recruiting, with 'not applicable' phases, and sponsored by hospitals. The analysis highlights the need for prospective registration and complete data fields.

Emergent BioSolutions' ACAM2000 vaccine approved by FDA for mpox prevention in high-risk individuals, based on safety data and animal study efficacy.